FDA’s Gottlieb: Any FDA/CMS Collaboration Efforts Should Occur Postmarket
This article was originally published in The Gray Sheet
Executive Summary
FDA and CMS should streamline their internal review processes before pursuing collaborative efforts to avoid an overly burdensome review process, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
You may also be interested in...
Will FDA/CMS Parallel Review Idea Make Headway This Time?
The possibility of simultaneous FDA and CMS evaluations of new devices is back in the front of agency officials' minds after a series of fits and starts over the past several years, says CMS Chief Medical Officer Barry Straube
Will FDA/CMS Parallel Review Idea Make Headway This Time?
The possibility of simultaneous FDA and CMS evaluations of new devices is back in the front of agency officials' minds after a series of fits and starts over the past several years, says CMS Chief Medical Officer Barry Straube
In Rare Move, CMS Cites FDA Warning Letter In National Coverage Request
CMS' internally-generated national coverage request for infrared therapy devices uncharacteristically refers to a recent FDA warning letter to manufacturer Anodyne Therapy